TXMD TherapeuticsMD Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TXMD

Price (delayed)

$2.17

Market cap

$25.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

$20.45M

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 50

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, ...

Highlights
The net income has soared by 53% YoY
TXMD's debt is down by 21% year-on-year and by 6% since the previous quarter
The company's EPS has shrunk by 200% QoQ but it has surged by 50% YoY
TXMD's revenue is up by 28% year-on-year but it is down by 2.5% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.therapeuticsmd.com
Peers: ABBV RPRX PFE

Key stats

What are the main financial stats of TXMD

TXMD stock price

How has the TherapeuticsMD stock price performed over time
Intraday
0.46%
1 week
-0.46%
1 month
5.34%
1 year
102.8%
YTD
33.13%
QTD
-1.81%

Financial performance

How have TherapeuticsMD's revenue and profit performed over time
Revenue
$3.27M
Gross profit
$3.27M
Operating income
-$3.95M
Net income
-$217,000
Gross margin
100%
Net margin
-6.6%
TXMD's net margin has surged by 63% year-on-year
The net income has soared by 53% YoY
TXMD's revenue is up by 28% year-on-year but it is down by 2.5% since the previous quarter
The gross profit has grown by 28% YoY but it has contracted by 2.5% from the previous quarter

Price vs fundamentals

How does TXMD's price correlate with its fundamentals

Growth

What is TherapeuticsMD's growth rate over time

Valuation

What is TherapeuticsMD stock price valuation
P/E
N/A
P/B
0.93
P/S
7.68
EV/EBIT
N/A
EV/EBITDA
13.94
EV/Sales
6.25
The company's EPS has shrunk by 200% QoQ but it has surged by 50% YoY
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 0.7
TXMD's revenue is up by 28% year-on-year but it is down by 2.5% since the previous quarter
TXMD's price to sales (P/S) is 25% lower than its 5-year quarterly average of 10.2 but 20% higher than its last 4 quarters average of 6.4

Efficiency

How efficient is TherapeuticsMD business performance
The company's return on sales has shrunk by 194% QoQ but it has surged by 72% YoY
The ROIC has plunged by 188% from the previous quarter but it has soared by 61% YoY
TherapeuticsMD's ROE has soared by 53% YoY
TXMD's return on assets has surged by 50% year-on-year

Dividends

What is TXMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXMD.

Financial health

How did TherapeuticsMD financials performed over time
TXMD's quick ratio is up by 20% year-on-year and by 6% since the previous quarter
TherapeuticsMD's current ratio has increased by 11% YoY and by 3.5% from the previous quarter
TXMD's debt is 83% smaller than its equity
TXMD's debt is down by 21% year-on-year and by 6% since the previous quarter
TXMD's debt to equity is down by 19% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.